Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

March 3, 2025

To whom it may concern

Company: TRYT Inc.
Representative: Hidetaka Sasai, President and Representative Director, CEO
(Securities code: 9164; Growth Market of the Tokyo Stock Exchange)
Contact: Takaaki Inoue, Managing Executive Officer, CFO, General Manager, Administration Department
Tel.: +81-6-6365-1131

Notice concerning Absorption-type Merger (Simplified Merger) of Consolidated Subsidiary

TRYT Inc. (the Company) hereby announces that the Company will absorb Medicle Inc. (Medicle), the Company's wholly owned subsidiary, effective May 1, 2025, as follows, at the meeting of its Board of Directors held on March 3, 2025.

Since the merger is simplified merger of a wholly owned subsidiary, therefore certain disclosure items and details are omitted.

1. Purpose of Merger

The Company has acquired 100% of the outstanding shares of Medicle, a provider of shift management applications for nurses and elderly care workers, effective March 3, 2025.

To enhance organizational operational efficiency, the Company will merge Medicle into its operations.

2. Outline of Merger

(1) Schedule of Merger

・Resolution of the Company's Board of Directors relating to the merger March 3, 2025
・Conclusion of merger agreement March 3, 2025
・Date of merger (effective date) May 1, 2025

(Note) The merger is, for the Company, a simplified merger under the provisions of Paragraph 2 of Article 796 of Companies Act. Therefore, the Company will not hold a general meeting of shareholder to carry out the merger.

(2) Method of Merger

It is an absorption-type merger in which the Company is the surviving company, and Medicle will be dissolved.

（3） Allotment Details pertaining to Merger

The Company, which owns all outstanding shares in Medicle, neither grants nor allots any shares or other consideration included money pertaining to the merger.

（4） Treatment of stock acquisition rights and bonds with stock acquisition rights of the merged company

Not applicable.

3． Overview of the Companies involved in Merger

(1) Overview of Surviving company

	Surviving company	
(1) Company Name	TRYT Inc.	
(2) Location	2-12-7, Sonezaki, Kita-ku, Osaka City	
(3) Name and Title of Representative	President and Representative Director Hidetaka, Sasai	
(4) Description of Business	Placement business and digital solutions for the medical and welfare industries	
(5) Capital	10 million yen (as of February 28, 2025)	
(6) Establishment	February 5, 2019	
(7) Number of Outstanding Shares	100,000,000 shares (as of February 28, 2025)	
(8) Fiscal Year End	December 31	
(9) Major Shareholders and Ratios of Shareholding	LIFE SCIENCE & DIGITAL HEALTH CO. LIMITED	60.00%
	JP MORGAN CHASE BANK 385632	4.44%
	J.P. MORGAN BANK LUXEMBOURG S.A. 381572	2.13%
	NORTHERN TRUST CO.(AVFC) RE NON TREATY CLIENTS ACCOUNT	1.90%
	Goldman Sachs Bank Europe SE, Luxembourg Branch	1.63%
	MLI FOR CLIENT GENERAL OMNI NON COLLATERAL NON TREATY-PB	1.60%
	Custody Bank of Japan, Ltd. (Trust account)	1.33%
	BBH BOSTON FOR NOMURA JAPAN SMALLER CAPITALIZATION FUND 620065	1.26%
	JPMCB USA RESIDENTS PENSION JASDEC LEND 385051	0.97%
	Nomura Securities Co., Ltd.	0.51%
(10) Financial Position and Results in Proceeding Fiscal Year		
	Fiscal year ended December 31, 2024 (IFRS Consolidated)	
Total Assets	77,563 millions of yen	

Total equity, Equity attributable to owners of parent	27,845 millions of yen
Equity attributable to owners of parent per share	278.45 yen
Revenue	57,116 millions of yen
Operating profit	5,186 millions of yen
Profit before tax	4,325 millions of yen
Profit, Profit attributable to owners of parent	2,917 millions of yen
Basic earnings per share	29.17 yen

(2) Overview of Company being merged

	Company being merged
(1) Company Name	Medicle Inc.
(2) Location	2-12-7, Sonezaki, Kita-ku, Osaka City
(3) Name and Title of Representative	President and Representative Director Motohiko, Terada
(4) Description of Business	Planning and providing applications for smartphone
(5) Capital	3. 5 million yen (as of February 28, 2025)
(6) Establishment	August 29, 2013
(7) Number of Outstanding Shares	350 shares (as of February 28, 2025)
(8) Fiscal Year End	July 31
(9) Major Shareholders and Ratios of Shareholding	TRYT Inc. 100%
(10) Financial Position and Results in Proceeding Fiscal Year	
	Fiscal year ended July 31, 2024 (Non-consolidated)
Total Assets	32 millions of yen
Net Assets	28 millions of yen
Net Assets per share	82,330 yen
Sales	18 millions of yen
Operating Income	△2 millions of yen
Ordinary Income	0 millions of yen
Profit	0 millions of yen
Earnings per share	609.15 yen

4． Conditions after Merger

The merger does not affect the Company’s name, location, representative’s title and name, business content, paid in capital or fiscal year end.

5. Future Outlook

Since the merger only involves the Company and its wholly-owned subsidiary, and has no significant impact on the consolidated financial results of the Company, its impact on consolidated business performance of the fiscal year ending December 31, 2025 will be negligible.

Reference: Consolidated Performance Forecast for the Fiscal Year Ending December 31, 2025 (released on February 13, 2025) and Actual Result of the Fiscal Year Ended December 31, 2024.

	Revenue	Operating profit	Profit before tax	Profit	Profit attributable to owners of parent
Consolidated earnings forecast for FY ending December 31, 2025	millions of yen 64,300	millions of yen 6,200	millions of yen 5,700	millions of yen 3,700	millions of yen 3,700
Actual result for FY ended December 31, 2024	millions of yen 57,116	millions of yen 5,186	millions of yen 4,325	millions of yen 2,917	millions of yen 2,917

*The aforementioned forecasts are based on the information available as of the date which this document is disclosed and contains unpredictable parameters that may cause the forecasts to vary. As such, our actual performances may differ from these forecasts depending on a variety of factors that will take shape from now on.